HOWL - NASDAQ
Werewolf Therapeutics, Inc.
$1.04
-3.7%Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
At a Glance
Live Snapshothowl
Total Current Assets
Last Annual Value
58.59M
3-Year CAGR
-25%
5-Year CAGR
-9%
10-Year CAGR
12%
Werewolf Therapeutics, Inc. Competitors Analysis of Total Current Assets
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Werewolf Therapeutics, Inc. NASDAQ:HOWL | 58.59M | -24.9% | -18.3% | N/A | |
 NRx Pharmaceuticals, Inc. NASDAQ:NRXP | 8.89M | 8.9% | -22.9% | N/A | |
 Outlook Therapeutics, Inc. NASDAQ:OTLK | 17388.97B | 8149.0% | 1418.9% | 345.3% | |
 Cibus, Inc. NASDAQ:CBUS | 12.07M | -30.0% | -4.5% | 8.2% | |
 Immunic, Inc. NASDAQ:IMUX | 22.87M | -24.2% | -26.3% | -9.4% | |
 PMV Pharmaceuticals, Inc. NASDAQ:PMVP | 115.23M | -17.8% | -17.5% | N/A | |
 Prelude Therapeutics Incorporated NASDAQ:PRLD | 105.69M | -23.4% | -18.6% | N/A | |
 Vaxart, Inc. NASDAQ:VXRT | 115.15M | 36.2% | -7.4% | 11.2% | |
 XBiotech Inc. NASDAQ:XBIT | 126.95M | -14.3% | -12.5% | 13.1% | |
 CEL-SCI Corporation AMEX:CVM | 6.06M | -4.3% | -33.1% | 0.3% | |
 CervoMed Inc. NASDAQ:CRVO | 43.08M | 62.9% | 2.6% | 39.0% |
Werewolf Therapeutics, Inc. Fair Value Envelope
Related Guides
Continue your HOWL research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.